首页 | 本学科首页   官方微博 | 高级检索  
     

100例肺结核咯血病人止血药的用药分析
引用本文:钟洪兰,谢立,黄乐珊. 100例肺结核咯血病人止血药的用药分析[J]. 现代医院, 2005, 5(1): 16-18
作者姓名:钟洪兰  谢立  黄乐珊
作者单位:1. 广州市胸科医院,广东,广州,510095
2. 广州市第二人民医院,广东,广州,510150
摘    要:目的 了解肺结核咯血病人止血药的利用情况。方法 采用回顾性调查方法 ,随机抽取第一诊断为肺结核咯血的住院病历 10 0份 ,对止血药的利用情况及相关内容进行统计分析。结果 ①病例使用止血药共计 13种 ,肾上腺色腙 (针、片 )、氨基己酸 (针、片 ) ,垂体后叶素、氨甲苯酸针分居止血药的第一、二、三、四位。②垂体后叶是大咯血首选药物 ,止血效果好。③止血药的联合用药占 79 0 %。④病例多联合抗感染治疗。结论 止血药的选用及止血效果与止血药的药理特点、病人基础疾病临床特点有关。

关 键 词:肺结核并咯血  药物利用  止血药  联合用药

ANALYSIS OF THE USE OF HEMOSTASIS DRUGS IN 100 PULMONARY TUBERCULOSIS PATIENTS WITH HEMOPTYSIS
Zhong Hong-lan,Xie Li,Huang Le-shanGuangzhou thoracic hospital,Guangdong province, PRC. ANALYSIS OF THE USE OF HEMOSTASIS DRUGS IN 100 PULMONARY TUBERCULOSIS PATIENTS WITH HEMOPTYSIS[J]. Modern Hospital, 2005, 5(1): 16-18
Authors:Zhong Hong-lan  Xie Li  Huang Le-shanGuangzhou thoracic hospital  Guangdong province   PRC
Affiliation:Zhong Hong-lan,Xie Li,Huang Le-shanGuangzhou thoracic hospital,Guangdong province,510095 PRC
Abstract:Objective To know the situation of hemostasis drugs utilization for pulmonary tuberculosis patients with hemoptysis. Methods Retrospectively investigate 100 randomly selected in-patient's record with the first diagnosis of pulmonary tuberculosis hemoptysis. Results ① The hemostasis drugs used for these patients were totally 13 kinds, among which adrenobazone (injection, tablet), aminocaproic acid (injection, tablet), pituitrin, aminomethylbenzoic acid injection rendered the 1st,2nd,3rd and the 4th position repectively. ②Pituitrin is the first choice for large amount hemoptysis achieving good effects. ③Combined use of hemostasis drugs rendered 79.0%. ④In most cases the anti-infection treatment were associated with. Conclusion The choice of hemostasis drugs and its effects are related to drug's pharmaceutical characteristics and patient's foundation of disease.
Keywords:Pulmonary tuberculosis hemoptysis   Use of drugs   Hemostasis drugs   Combined use of drugs
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号